Robert W Frenck1, Anne Fiquet2, Alejandra Gurtman3, Martin van Cleeff4, Matthew Davis5, John Rubino6, William Smith7, Vani Sundaraiyer8, Mohinder Sidhu9, Emilio A Emini10, William C Gruber11, Daniel A Scott12, Beate Schmoele-Thoma13. 1. Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Electronic address: Robert.Frenck@cchmc.org. 2. Pfizer Vaccines Research, Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS, UK. Electronic address: anne.fiquet@pfizer.com. 3. Pfizer Vaccines Research, Pfizer Inc, 401 North Middletown Road, Pearl River, NY 10965, USA. Electronic address: alejandra.gurtman@pfizer.com. 4. Cary Medical Research, Cary, NC, USA. Electronic address: mvancleeff@carymedicalgroup.com. 5. Rochester Clinical Research, Rochester, NY, USA. Electronic address: mdavis@rcrclinical.com. 6. Raleigh Medical Group, 3521 Haworth Dr, Raleigh, NC, USA. Electronic address: jrubino@pmg-research.com. 7. Volunteer Research Group at The University of Tennessee Medical Center, Knoxville, TN, USA. Electronic address: wbsmd@noccr.com. 8. inVentiv Health Clinical, LLC, 504 Carnegie Center, Princeton, NJ 08540, USA. Electronic address: Vani.Sundaraiyer@inventivhealth.com. 9. Pfizer Vaccines Research, Pfizer Inc, 401 North Middletown Road, Pearl River, NY 10965, USA. Electronic address: mohinderjitsidhu@yahoo.com. 10. Pfizer Vaccines Research, Pfizer Inc, 401 North Middletown Road, Pearl River, NY 10965, USA. Electronic address: Emilio.Emini@gatesfoundation.org. 11. Pfizer Vaccines Research, Pfizer Inc, 401 North Middletown Road, Pearl River, NY 10965, USA. Electronic address: bill.gruber@pfizer.com. 12. Pfizer Vaccines Research, Pfizer Inc, 401 North Middletown Road, Pearl River, NY 10965, USA. Electronic address: dan.scott@pfizer.com. 13. Pfizer Vaccines Research, Pfizer GmbH, Linkstraße 10, 10785 Berlin, Germany. Electronic address: Beate.Schmoele-Thoma@Pfizer.com.
Abstract
BACKGROUND: Vaccination effectively reduces invasive disease and pneumonia caused by Streptococcus pneumoniae. However, waning antibody titers and the ability of revaccination to boost titers in older adults have been concerns. A study to describe antibody persistence after vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) and response to revaccination 5 years after the initial dose was conducted. METHODS:Pneumococcal vaccine-naive subjects aged 50-59 years were randomized and vaccinated with PCV13 plus trivalent inactivated influenza vaccine concomitantly or 1 month apart, then revaccinated with PCV13 five years later. Antipneumococcal polysaccharide opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) were determined before and approximately 1 month after each vaccination. Targeted local reactions and systemic events were collected for 14 days, adverse events (AEs) for 1 month, and serious AEs (SAEs) for 6 months after each vaccination. RESULTS:Of 1116 randomized subjects, 727 were revaccinated at year 5. Between the time of initial vaccination and revaccination, OPA GMTs and IgG GMCs declined but remained higher than levels before initial vaccination for 12 of the 13 vaccine serotypes. One month after revaccination, OPA GMTs and IgG GMCs were comparable with, or higher than, levels observed 1 month after initial vaccination for most vaccine serotypes. Local reactions were mostly mild. AEs were reported by <5% and SAEs by <1% of subjects at 1 and 6 months after revaccination, respectively. No SAEs were vaccine-related. CONCLUSIONS: Revaccination of adults ≥50 years with PCV13 five years after primary vaccination was safe and immunogenic. Additionally, antibody titers were maintained for at least 5 years after vaccination. The vaccine stimulated a memory response as shown by enhanced responses that were maintained or enhanced by revaccination. CLINICALTRIALS. GOV REGISTRATION: NCT00521586.
RCT Entities:
BACKGROUND: Vaccination effectively reduces invasive disease and pneumonia caused by Streptococcus pneumoniae. However, waning antibody titers and the ability of revaccination to boost titers in older adults have been concerns. A study to describe antibody persistence after vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) and response to revaccination 5 years after the initial dose was conducted. METHODS:Pneumococcal vaccine-naive subjects aged 50-59 years were randomized and vaccinated with PCV13 plus trivalent inactivated influenza vaccine concomitantly or 1 month apart, then revaccinated with PCV13 five years later. Antipneumococcal polysaccharide opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) were determined before and approximately 1 month after each vaccination. Targeted local reactions and systemic events were collected for 14 days, adverse events (AEs) for 1 month, and serious AEs (SAEs) for 6 months after each vaccination. RESULTS: Of 1116 randomized subjects, 727 were revaccinated at year 5. Between the time of initial vaccination and revaccination, OPA GMTs and IgG GMCs declined but remained higher than levels before initial vaccination for 12 of the 13 vaccine serotypes. One month after revaccination, OPA GMTs and IgG GMCs were comparable with, or higher than, levels observed 1 month after initial vaccination for most vaccine serotypes. Local reactions were mostly mild. AEs were reported by <5% and SAEs by <1% of subjects at 1 and 6 months after revaccination, respectively. No SAEs were vaccine-related. CONCLUSIONS: Revaccination of adults ≥50 years with PCV13 five years after primary vaccination was safe and immunogenic. Additionally, antibody titers were maintained for at least 5 years after vaccination. The vaccine stimulated a memory response as shown by enhanced responses that were maintained or enhanced by revaccination. CLINICALTRIALS. GOV REGISTRATION: NCT00521586.
Authors: David Fitz-Patrick; Mariano Young; Daniel A Scott; Ingrid L Scully; Gary Baugher; Yahong Peng; Kathrin U Jansen; William Gruber; Wendy Watson Journal: Hum Vaccin Immunother Date: 2021-02-05 Impact factor: 3.452
Authors: Donald Hurley; Carl Griffin; Mariano Young; Daniel A Scott; Michael W Pride; Ingrid L Scully; John Ginis; Joseph Severs; Kathrin U Jansen; William C Gruber; Wendy Watson Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Randall Severance; Howard Schwartz; Ron Dagan; Laurie Connor; Jianing Li; Alison Pedley; Jonathan Hartzel; Tina M Sterling; Katrina M Nolan; Gretchen M Tamms; Luwy K Musey; Ulrike K Buchwald Journal: Hum Vaccin Immunother Date: 2021-11-02 Impact factor: 3.452